 DUBLIN, June 24, 2021 PRNewswire -- Theravance Biopharma, Inc. NASDAQ: TBPH Theravance Biopharma, a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, announced today the pricing of its underwritten public offering of 6,700,000 ordinary shares at a price to the public of 15.00 per share. The gross proceeds to Theravance Biopharma from the offering are expected to be 100.5 million, before deducting underwriting discounts and commissions and estimated offering expenses. 